✉ Email this page to a colleague
« Back to Dashboard
Retosiban is an investigational drug.
There have been 8 clinical trials for Retosiban. The most recent clinical trial was a Phase 3 trial, which was initiated on February 29th 2016.
The most common disease conditions in clinical trials are Obstetric Labor, Premature, Premature Birth, and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline, PPD, and Tel-Aviv Sourasky Medical Center.
There are sixteen US patents protecting this investigational drug and one hundred and thirty-four international patents.
Recent Clinical Trials for Retosiban
|Tocolytic Therapy for Preterm Labor in Multiple Gestation||Tel-Aviv Sourasky Medical Center||Phase 3|
|A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor||PPD||Phase 3|
|A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor||GlaxoSmithKline||Phase 3|
Top disease conditions for Retosiban
Top clinical trial sponsors for Retosiban
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Retosiban||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Retosiban||See Plans and Pricing||Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies||Ferring B.V. (Hoofddorp, NL)||See Plans and Pricing|
|Retosiban||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Retosiban||See Plans and Pricing||Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof||Merck Serono S.A. (Coinsins, CH)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Retosiban||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|Retosiban||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|Retosiban||China||CN107847398||2036-05-05||See Plans and Pricing|
|Retosiban||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|